Results 31 to 40 of about 7,124 (172)
Drug-associated porphyria: a pharmacovigilance study
Orphanet Journal of Rare DiseasesBackground The potentially fatal attacks experienced by porphyria carriers are triggered by various porphyrinogenic drugs. However, determining the safety of particular drugs is challenging. Methods We retrospectively used the U.S.
Qi Wang +4 more
doaj +1 more source
Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions
Clinical Endocrinology, EarlyView.ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley +1 more source
BMC NeurologyBackground Acute intermittent porphyria (AIP) is a rare but treatable disease. COVID-19 has various possible complications including posterior reversible encephalopathy syndrome (PRES).
Hideo Handa +7 more
doaj +1 more source
High penetrance, recurrent attacks and thrombus formation in a family with hereditary coproporphyria
JIMD Reports, 2022 Hereditary coproporphyria (HCP) is the rarest of the autosomal dominant acute porphyrias with an estimated incidence of 0.02 per 10 million per year.
Cindy Towns +4 more
doaj +1 more source
Tolerability of hormonal treatments in acute hepatic porphyria patients
Internal Medicine Journal, EarlyView.Abstract Background Acute hepatic porphyria (AHP) flares have been associated with female hormones and the use of hormonal treatments. Women with AHP are traditionally advised to avoid exogenous oestrogen and progesterone, limiting options for contraception and management of menorrhagia, dysmenorrhoea and menopausal symptoms.
Andjela Arandjelovic +2 more
wiley +1 more source
Journal of Clinical and Translational Hepatology, 2015 The porphyrias comprise a set of diseases, each representing an individual defect in one of the eight enzymes mediating the pathway of heme synthesis. The diseases are genetically distinct but have in common the overproduction of heme precursors. In the case of the acute (neurologic) porphyrias, the cause of symptoms appears to be overproduction of a ...
Bissell, D Montgomery, Wang, Bruce
openaire +4 more sources
Gynecologic Oncology Reports, 2021 Porphyria Cutanea Tarda (PCT) is a rare paraneoplastic syndrome. The effects of therapeutic ionizing radiation in patients with PCT are not well understood.
Sarah Z. Hazell +2 more
doaj +1 more source
Pain Practice, Volume 26, Issue 7, September 2026.ABSTRACT Background Complex regional pain syndrome type 1 (CRPS1) is a disabling pain syndrome whose treatment remains challenging. Mesotherapy is a therapeutic method involving the injection of low doses of active substances through the skin. No studies assessed mesotherapy in CRPS1 patients.
Philippe Lafuma +12 more
wiley +1 more source
Photodermatology, Photoimmunology &Photomedicine, Volume 42, Issue 5, September 2026.ABSTRACT Background/Purpose Visible light (VL), and particularly high‐energy visible light (HEVL), reaching Earth's surface has emerged as a relevant contributor to skin damage. VL has been implicated in oxidative stress, inflammation, pigmentation disorders, and photoaging, especially in individuals with darker skin phototypes.
Azahara Rodríguez‐Luna +5 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 8, August 2026.ABSTRACT Radiation therapy (RT) is a mainstay of treatment for a myriad of cancers, often utilized for tumors that are unable to be resected, as well as an adjunct to surgery and chemotherapy. Unfortunately, many cancers are resistant to RT‐induced damage and subsequent cell death.
Joseph Carmicheal +4 more
wiley +1 more source